DIQTA 1.0: Drug-Induced QT Prolongation Atlas

PEMIGATINIB

Classification:Ambiguous

Severity Score:1.0

ADVERSE REACTIONS
Clinical Trials Experience
Dosage interruptions due to an adverse reaction occurred in 43% of patients who received PEMAZYRE. Adverse reactions requiring dosage interruption in 1% of patients included stomatitis, palmar-plantar erythrodysesthesia syndrome, arthralgia, fatigue, abdominal pain, AST increased, asthenia, pyrexia, ALT increased, cholangitis, small intestinal obstruction, alkaline phosphatase increased, diarrhea, hyperbilirubinemia, electrocardiogram QT prolonged, decreased appetite, dehydration, hypercalcemia, hyperphosphatemia, hypophosphatemia, back pain, pain in extremity, syncope, acute kidney injury, onychomadesis, and hypotension.
CLINICAL PHARMACOLOGY
Pharmacodynamics
Cardiac Electrophysiology
At a dose 1.5 times the maximum recommended dose, PEMAZYRE does not result in a large mean increase (i.e. >20 ms) of the QTc interval.

Current Drug

Other Drugs

QT Prolongation

24092

Other ADRs

38381587

Odds Ratio = N/A

ATC Code(s):

Active Ingredient:PEMIGATINIB

Active Ingredient UNII:Y6BX7BL23K

Drugbank ID:DB15102

PubChem Compound:N/ADIR Classification

PharmGKB:

CAS Number:1513857-77-6

Dosage Form(s):tablet

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F

N/A